ILC2 Activation in the Choroid Plexus for Aging-Related Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The roles and regulation of immune cells, particularly tissue-resident lymphocytes, in maintaining cognitive function and combating neurodegenerative disorders such as Alzheimer's Disease, are poorly understood, and aging affects immune cell function and increases susceptibility to cognitive decline.
Innovation Solution
Implanting or activating group-2 innate lymphoid cells (ILC2) in the choroid plexus using activators like IL-33, IL-25, or IL-7 to enhance their activity, which produces cytokines that alleviate cognitive decline and reduce neuroinflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune cells are introduced to combat neurodegenerative disorders, then cognitive function is improved, but the complexity of the treatment and understanding of mechanisms increases
Solution Approach 1:
The patent uses ILC2 cells as intermediary agents that mediate between the administered activators (IL-33, IL-25, IL-7) and the brain tissue. These cells serve as a bridge to deliver protective effects (reduced neuroinflammation, improved cognition) without requiring direct administration of complex immune cell mixtures or poorly understood mechanisms into the brain.
2Reliability
If ILC2 cells are activated using multiple activators, then cognitive function improves, but the number of substances and treatment steps increases
Solution Approach 1:
The patent explores changing the activation state of ILC2 cells by administering different cytokine activators (IL-33, IL-25, IL-7) at various doses and time points. By modulating the activation parameters rather than using multiple simultaneous treatments, the patent achieves cognitive improvement while managing treatment complexity.
Solution Approach 2:
The patent investigates whether partial activation of ILC2 cells using single or selective combinations of activators is sufficient to achieve cognitive benefits, rather than requiring full activation with all possible activators. This approach reduces the quantity of substances needed while maintaining therapeutic efficacy.
Data Source
AI summary
The present disclosure relates to a method of improving cognitive function in a subject. The method includes implanting group-2 innate lymphoid cells (ILC2) in a cranium of a subject, where the ILC2 was treated with an ILC2 activator. The present disclosure further relates to a method including selecting a subject having aging-associated cognitive decline and administering to the subject an activator of innate lymphoid cell activity under conditions effective to promote innate lymphoid cell activity. The present disclosure further relates to a method of improving cognition in a subject. The method includes selecting a subject having aging-associated cognitive decline and administering to the subject a cytokine selected from the group consisting of IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin.